Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
|
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
  • [41] A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
    Gupta, Shilpa
    Argiles, Guillem
    Munster, Pamela N.
    Hollebecque, Antoine
    Dajani, Olav
    Cheng, Jonathan D.
    Wang, Ruixue
    Swift, Ann
    Tosolini, Alessandra
    Piha-Paul, Sarina A.
    CLINICAL CANCER RESEARCH, 2015, 21 (23) : 5235 - 5244
  • [42] A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs)
    Reidy-Lagunes, Diane
    Pietanza, M. Catherine
    Sega, Michal
    Capanu, Marinela
    Saltz, Leonard
    PANCREAS, 2014, 43 (03) : 503 - 503
  • [43] A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs).
    Reidy, Diane Lauren
    Pietanza, Maria Catherine
    Segal, Michal
    Capanu, Marinela
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
    Konopleva, Marina Y.
    Walter, Roland B.
    Faderl, Stefan H.
    Jabbour, Elias J.
    Zeng, Zhihong
    Borthakur, Gautam
    Huang, Xuelin
    Kadia, Tapan M.
    Ruvolo, Peter P.
    Feliu, Jennie B.
    Lu, Hongbo
    Debose, LaKiesha
    Burger, Jan A.
    Andreeff, Michael
    Liu, Wenbin
    Baggerly, Keith A.
    Kornblau, Steven M.
    Doyle, L. Austin
    Estey, Elihu H.
    Kantarjian, Hagop M.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2226 - 2235
  • [45] Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
    Yan Xing
    Nancy U. Lin
    Matthew A. Maurer
    Huiqin Chen
    Armeen Mahvash
    Aysegul Sahin
    Argun Akcakanat
    Yisheng Li
    Vandana Abramson
    Jennifer Litton
    Mariana Chavez-MacGregor
    Vicente Valero
    Sarina A. Piha-Paul
    David Hong
    Kim-Anh Do
    Emily Tarco
    Dianna Riall
    Agda Karina Eterovic
    Gerburg M. Wulf
    Lewis C. Cantley
    Gordon B. Mills
    L. Austin Doyle
    Eric Winer
    Gabriel N. Hortobagyi
    Ana Maria Gonzalez-Angulo
    Funda Meric-Bernstam
    Breast Cancer Research, 21
  • [46] Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
    Kalinsky, Kevin
    Sparano, Joseph A.
    Andreopoulou, Eleni
    Taback, Bret
    Wlechmann, Lisa Silvia
    Feldman, Sheldon M.
    Ananthakrishnan, Preya
    Hibshoosh, Hanina
    Manavaian, John
    Crew, Katherine D.
    Maurer, Matthew A.
    Hershman, Dawn L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
    Kalinsky, K.
    Sparano, J. A.
    Kim, M.
    Crew, K. D.
    Maurer, M. A.
    Taback, B.
    Feldman, S. M.
    Hibshoosh, H.
    Wiechmann, L.
    Adelson, K. B.
    Hershman, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
    Xing, Yan
    Lin, Nancy U.
    Maurer, Matthew A.
    Chen, Huiqin
    Mahvash, Armeen
    Sahin, Aysegul
    Akcakanat, Argun
    Li, Yisheng
    Abramson, Vandana
    Litton, Jennifer
    Chavez-MacGregor, Mariana
    Valero, Vicente
    Piha-Paul, Sarina A.
    Hong, David
    Do, Kim-Anh
    Tarco, Emily
    Riall, Dianna
    Eterovic, Agda Karina
    Wulf, Gerburg M.
    Cantley, Lewis C.
    Mills, Gordon B.
    Doyle, L. Austin
    Winer, Eric
    Hortobagyi, Gabriel N.
    Gonzalez-Angulo, Ana Maria
    Meric-Bernstam, Funda
    BREAST CANCER RESEARCH, 2019, 21 (1):
  • [49] A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+breast cancer
    Nazeef, Moniba
    Tevaarwerk, Amye J.
    Eickhoff, Jens
    Burkard, Mark E.
    Heideman, Jennifer
    Liu, Glenn
    Flynn, Chris
    Kolesar, Jill M.
    Wisinski, Kari B.
    CANCER RESEARCH, 2015, 75
  • [50] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
12345